HC Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktail By Investing.com – Investing.com

HC Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktail By Investing.com – Investing.com

By Sam Boughedda

Investing.com — Aridis Pharmaceuticals Inc 's (NASDAQ:) monoclonal antibody cocktail treatment is potentially first-in-class, H.C. Wainwright analyst Vernon Bernardino told investors Wednesday.

Last week Aridis announced that the drug, AR-701, is broadly reactive against Omicron and other Covid-19 variants, SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome Coronavirus), and the common cold, which is a type of human coronavirus.